Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection

NCT04594785 | Unknown

• 1 other identifier: RECHMPL20_0550
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions. Some of them are delayed and provide Post infectious inflammatory reaction (PIIR), they are challenging for diagnosis and for management. Clinician have to avoid unnecessary antibiotic thearapy and in if necessary have to give immunosuppressive therapy. Except for rheumatic disease for group A streptococcus (GAS) infections there are not stanrdized diagnostic criteria and therapeutic protocol, and PIIR have probably a suboptimal management. In this context the investigators aim to explore PIIR in the 3 most frequent bacterial invasive infection in France, by a retrospective monocentric study. The investigators include all children betwwen 2012 and 2018 hospitalized for infections by Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and GAS invasive infections.

Conditions

Streptococcus Pneumonia; Streptococcus Pyogenes Infection; Neisseria Meningitides Meningitis

Keywords

post-infectious inflammatory reactions; Neisseria Meningitis

Outcome Measures

Primary Outcomes (1)

• Describe the frequency PIIRs

  Describe the frequency PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection

  1 day

Secondary Outcomes (1)

• Characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection

  1 day

Other Outcomes (1)

• Predictors of PIIRs

  1 day

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pediatric population

You may qualify if:

• Less than 18 years of age
• Fever associated with GAS, NM, or SP invasive infection

You may not qualify if:

• age \> 18 years
• Impossibility to obtain the consent of parents / legal representatives.

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

RECRUITING

MeSH Terms

Conditions

Pneumonia; Streptococcal Infections; Meningitis, Meningococcal

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Lung Diseases; Respiratory Tract Diseases; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Meningitis, Bacterial; Central Nervous System Bacterial Infections; Meningococcal Infections; Neisseriaceae Infections; Gram-Negative Bacterial Infections; Central Nervous System Infections; Central Nervous System Diseases; Nervous System Diseases; Meningitis; Neuroinflammatory Diseases

Study Officials

• Eric JEZIORSKI

  University Hospital, Montpellier

  STUDY DIRECTOR

Central Study Contacts

Eric JEZIORSKI

CONTACT

04 67 33 57 98; e-jeziorski@chu-montpellier.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2020
• First Posted: October 20, 2020
• Study Start: October 1, 2020
• Primary Completion: December 1, 2021
• Study Completion: December 30, 2021
• Last Updated: October 28, 2020

Record last verified: 2020-10

Locations

FR (1)